ArticleACS omega2025
From Formulation to Function: γ‑Oryzanol Solid Dispersion Development and Its Neuroprotective Effects on the Depression Model.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Exploring the mechanisms and therapeutic role of γ-oryzanol in neuropathic pain: a systematic review.Inflammopharmacology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Major depressive disorder (MDD) is a prevalent psychiatric condition linked to suicide risk and public health impact. Current antidepressants often cause side effects and have delayed efficacy, driving interest in natural compounds with antioxidant properties as alternative treatments. γ-Oryzanol (GO) exhibits antioxidant, neuroprotective, and antidepressant properties that warrant investigation. However, its clinical application is restricted due to its water-insoluble properties, which lead to poor oral bioavailability. Therefore, this study aimed to develop a γ-oryzanol solid dispersion (GOSD) to improve GO water solubility. Then, its neuroprotective effects against dexamethasone-induced toxicity in SK-N-SH cells were evaluated to forge a clear link between the formulation and the function. The GOSD was successfully developed by using a solvent melting method. The developed GOSD could enhance the water solubility of GO up to 1.37 ± 0.05 mg/mL and enabled GO release under simulated intestinal conditions, indicating oral bioavailability improvement. In addition, the GOSD maintained good physical and chemical stability under a 6-month storage period at room temperature. Regarding the neuroprotective potential of the GOSD, our findings indicated that all tested concentrations were nontoxic to SK-N-SH cells. Interestingly, through the enhanced water solubility of GO, GOSD pretreatment demonstrated superior neuroprotective efficacy over free GO against dexamethasone-induced cytotoxicity. GOSD pretreatment prior to dexamethasone exposure significantly decreased abnormal and apoptotic cells by reducing ROS levels and increasing the SOD activity. Remarkably, GOSD pretreatment restored synaptic plasticity through multiple mechanisms: reducing MAO activity, suppressing GR expression, and upregulating synaptophysin expression. These results strongly support the GOSD as a safe and effective alternative therapeutic approach for treating depressive disorders.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.